Table 3.
Summary of potential peptide therapies for SARS.
| Peptide Name | Sequence | Derived from | Target | IC50 | Assay Format Tested | Phase | Reference |
|---|---|---|---|---|---|---|---|
| P8 | PSSKRFQPFQQFGRDVSDFT | S protein | ACE2 receptor | * | Syncytia inhibition assay | Pre-clinical | [133] |
| P9 | CANLLLQYGSFCTQLNRALSGIA | S protein | ACE2 receptor | * | Syncytia inhibition assay | Pre-clinical | [133] |
| P2 | PTTFMLKYDENGTITDAVDC | S protein | ACE2 receptor | 112.5 μg /mL, (IC90) | Cytopathic effect (CPE)-based assay | Pre-clinical | [232] |
| P6 | YQDVNCTDVSTAIHADQLTP | S protein | ACE2 receptor | 113.0 μg /mL, (IC90) | Cytopathic effect (CPE)-based assay | Pre-clinical | [232] |
| P8 | QYGSFCTQLNRALSGIAAEQ | S protein | ACE2 receptor | 24.9 μg /mL, (IC90) | Cytopathic effect (CPE)-based assay | Pre-clinical | [232] |
| P10 | IQKEIDRLNEVAKNLNESLI | S protein | ACE2 receptor | 73.5 μg /mL, (IC90) | Cytopathic effect (CPE)-based assay | Pre-clinical | [232] |
| S471−503 | ALNCYWPLNDYGFYTTTGIGYQPYRWVLSFEL | S protein | ACE2 receptor | * | Competition ELISA, plaque assay | Pre-clinical | [95] |
| SNA5 | GGGWFCPIVRGRVSC | Phage display library | N protein | n/a | Monoclonal phage ELISA | Pre-clinical | [128] |
| octapeptide | AVLQSGFR | Structure-based drug design and modeling | Mpro | 2.7 × 10−2 mg/L | Cytopathic effect (CPE)-based assay | Pre-clinical | [39] |
| P9 | NGAICWGPCPTAFRQIGNCGHFKVRCCKIR | β-defensin-4 | Endosome acidification | 5 μg/mL | plaque reduction assay | Pre-clinical | [231] |
*not available in the literature.